source
- STAT+: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industryShould the federal government try to slow — or even block — U.S. biotech deals that could benefit China?STAT · 1mo ago↗ source
- STAT+: How a biotech turned a trial failure into an AI modelIn this edition of STAT Health Tech: How a biotech startup turned a failed clinical trial into an AI model, and more.STAT · 1mo ago↗ source
- Lilly buys non-opioid pain drugmaker 4EIt’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.BioPharma Dive · 1mo ago↗ source